ASH 2019 | Myeloma updates: TAK-079, quadruplet regimens, MRD & bone disease
Noopur Raje
• 7 Dec 2019
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, highlights the key updates in the multiple myeloma (MM) field from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. Prof. Raje specifically discusses data for the anti-CD38 monoclonal antibody TAK-079, four-drug combination regimens, as well as MRD testing to assess deep responses in MM and bone disease.
